Latest Deals

Credit: HJBC via Shutterstock

Fulcrum Therapeutics has signed a $1bn exclusive licence deal with Sanofi to develop and commercialise the investigational facioscapulohumeral muscular dystrophy (FSHD) drug losmapimod. Sanofi gains exclusive commercialisation rights for losmapimod outside of the US. Fulcrum will receive upfront payment of $80m and is eligible to receive up to $975m in specified regulatory and sales-based milestones. The drug is currently being investigated in the Phase III REACH clinical trial (NCT05397470). 

Galapagos has signed a strategic partnership with Blood Centers of America (BCA) to expedite the decentralised production of its chimeric antigen receptor (CAR)-T cell therapies in the US. The deal will facilitate in the good manufacturing practice (GMP)-compliant manufacturing of Galapagos’ CAR-T haemato-oncology clinical programme. This partnership will utilise BCA’s extensive network, spanning over 50 community blood centres in 43 states. 

Novo Nordisk has entered a research partnership with Flagship Pioneering and Metaphore Biotechnologies to jointly develop up to two next-generation therapeutics for the management of obesity. The collaboration forms part of a strategic deal between Novo Nordisk and Flagship, focusing on new treatment approaches for cardiometabolic and rare diseases.

Angle has reached an agreement with AstraZeneca to develop a Parsotix-based Androgen Receptor (AR) assay for use in prostate cancer studies. Under the £550,000 agreement, Angle will develop the assay in its UK laboratories. The company says the development of the assay will demonstrate the importance of its Parsortix system in assessing the efficacy of prostate cancer therapeutics.